Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are the standard treatment for non‐small cell lung cancer (NSCLC) with EGFR activating mutations (e.g., Ex19del or L858R).1, 2. Here, EGFR is linked to non-small cell lung carcinoma.